With the prevalence of chronic diseases like cancer and autoimmune disorders at its peak, the spotlight is falling on immunomodulators. Courtesy of this, Future Market Insights’ updated report finds the global immunomodulator market size will reach USD 88.6 billion in 2024.
Development of more effective and safe immunotherapies will further boost sales growth, resulting in total market valuation reaching a staggering USD 178.0 billion by 2034. Global immunomodulator demand is forecast to surge at 7.2% CAGR throughout the forecast period.
A close contest is being observed between immunostimulants and immunosuppressants in the market, with the latter product category leading just by a margin of 2% share in 2023. Growing adoption of immunosuppressants for treating autoimmune disorders is giving them a slight edge over immunostimulants.
Market Forecast for Immunomodulator Industry
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | USD 81.7 billion |
| Market Size in 2024 | USD 88.6 billion |
| Market Revenue in 2034 | USD 178.0 billion |
| Value-based CAGR (2024 to 2034) | 7.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The immunotherapy field is rapidly evolving, holding great potential for companies indulging in this business. One of the prominent factors behind the robust growth of the immune system modulator industry is the escalating prevalence of chronic diseases like psoriasis, HIV/AIDS, cancer, and anti-inflammatory bowel disease.
Immunomodulators are rising to prominence due to their ability to alter the function of the immune system. Depending on the desired therapeutic outcome, these medications can enhance or suppress the immune response.
Growing adoption of immune system modulators for treating several health conditions where the immune system is either underactive or overactive is set to boost market growth. Similarly, easy availability of a wide range of immune system modulators will bode well for the market.
Patients with chronic diseases, particularly autoimmune disorders, are opting for various immunomodulatory medications to manage their condition and reduce symptoms. These include cytokines, monoclonal antibodies, and even vaccines, probiotics, and probiotics.
On the other hand, the market is also facing certain challenges that might limit its growth during the next decade. These include side effects of immune system modulation drugs and stringent regulatory policies for approval of antibodies.
Global sales of immunomodulators increased at a CAGR of 9.4% during the historical period, with total market valuation reaching USD 81.7 billion in 2023. In the next ten years, a CAGR of 7.2% has been predicted for the target industry, depicting a deduction of 2.2% CAGR from the historical period.
Multiple factors are predicted to stimulate growth of the immunomodulator market during the forecast period. These include growing health awareness, increasing incidence of chronic diseases, and surging adoption of immunity system modulators.
Growing awareness among both patients and healthcare professionals about the benefits of monoclonal therapy in immunomodulation will benefit the market. Similarly, increasing government support will encourage more and more companies to launch research into the immunotherapy field.
To gain maximum benefits, key players are concentrating on developing novel immune system modulators with better efficacy and fewer side effects. This will bode well for the market.
Principal Consultant
High Prevalence of Chronic Diseases
One of the prominent reasons behind the robust growth of the immunomodulatory therapeutics market is the growing incidence of chronic diseases. There is a spike in cases of diseases like cancer, asthma, multiple sclerosis, etc. This, in turn, is creating a greater demand for medications like immune system modulators.
High adoption of novel therapy for treating Crohn’s disease is another key factor impacting market growth. Subsequently, rise in organ transplantation will continue to uplift demand for immunomodulators like immunosuppressants through 2034.
Widening Applications in Oncology
Immune system modulators are gaining wider popularity in cancer treatments, especially in immunotherapy-based methods like chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint. This increasing application in the oncology segment will boost market growth through 2034.
The section comprehensively evaluates three interrelated markets: the global immune system modulatory industry, the immunostimulants market, and the allergy immunotherapy industry. It dissects each market's distinctive characteristics, encompassing their respective CAGRs, while delving into the pivotal factors influencing their growth trajectories.
Global Immunomodulator Drug Industry Forecast:
| Attribute | Global Immunomodulator Drug Industry Forecast |
|---|---|
| CAGR (2024 to 2034) | 7.2% |
| Industry Growth Factors for Immunomodulating Drugs | A spike in the prevalence of chronic diseases and surging demand for targeted immunomodulatory therapies are providing impetus for market growth. |
| Key Trends in Immunomodulator Market | Key growth-shaping trends include the development of novel immunotherapies and the high usage of immunosuppressants during organ implantation. |
Global Immunostimulant Market Forecast:
| Attribute | Global Immunostimulant Market Forecast |
|---|---|
| CAGR (2024 to 2034) | 6.2% |
| Growth Factor | Key growth influencing factors include high prevalence of cancer, asthma, allergic conditions, and other chronic diseases and availability of effective product pipelines of immunostimulant manufacturing companies. |
| Key Trends in Immunostimulant Market | Development of novel immunostimulants and rise in FDA approvals will benefit the market. |
Global Allergy Immunotherapy Market Analysis:
| Attribute | Global Allergy Immunotherapy Market Analysis |
|---|---|
| CAGR (2024 to 2034) | 8.9% |
| Growth Factor | Increasing prevalence of allergies and escalating demand for effective treatment options are fueling market growth. |
| Key Allergy Immunotherapy Market Trends | Key growth influencing trends include growing interest in personalized medicine and development of advanced immunotherapy treatments like biologics, immunoglobulin E (IgE) inhibitors, and gene therapies. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below shows the estimated growth rates of the key countries. South Korea and Japan are set to record high CAGRs of 9.3% and 8.7%, respectively, through 2034.
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 7.5% |
| United Kingdom | 8.4% |
| China | 7.9% |
| Japan | 8.7% |
| South Korea | 9.3% |
The table below highlights key countries’ market revenues. The United States and China are forecast to witness high immune modulator consumption, with predicted valuations of USD 32 billion and USD 28.1 billion, respectively, in 2034.
| Countries | Market Revenue (2034) |
|---|---|
| United States | USD 32 billion |
| United Kingdom | USD 7.2 billion |
| China | USD 28.1 billion |
| Japan | USD 19.6 billion |
| South Korea | USD 11.5 billion |
The United States continues to remain a hotbed for immune system modulator manufacturers. This can be attributed to increasing prevalence of chronic diseases, high healthcare expenditure, and growing interest in personalized medicine.
As per FMI’s updated report, demand for immunomodulators in the United States is projected to record a CAGR of 7.5% during the next decade. This will push the total market in the nation to a staggering USD 32 billion by 2034.
The United States is witnessing high prevalence of cancer, asthma, and autoimmune disorders like multiple sclerosis and arthritis. For instance, according to John Hopkins University, around 10 million people in the United States are affected by autoimmune disorders. This will play a vital role in fueling product demand.
Therapies are being widely used to manage symptoms of autoimmune diseases and slow their progression. Thus, as the incidence of these diseases surges, so will sales of immune system modulators.
The United States is home to several top pharmaceutical giants like Merck, Bristol-Myers Squibb, and Eli Lilly. These companies are constantly investing in immunotherapy research and development to develop novel drugs for different applications.
China, with its high chronic disease patient pool, is poised to record a CAGR of 7.9% throughout the forecast period. By 2034, sales in China are estimated to be valued at USD 28.1 billion.
Multiple factors are fueling sales in China. These include growing geriatric population, escalating awareness of immunological disorders and their treatments, and favorable government support for the biopharmaceutical industry.
China is witnessing a spike in the geriatric population, which is more prone to immunological disorders due to weakened immune systems. This, in turn, is uplifting demand for immunomodulators to manage age-related health conditions.
Growing focus on indigenous research and development efforts is leading to development of homegrown immunotherapies in China. Similarly, ongoing regulatory changes are creating a favorable environment for market development, streamlining drug approvals, and promoting innovation in immune system modulator landscape.
The section below provides deeper insights into top segments and their respective growth rate. This information can help companies act accordingly and strengthen their presence in lucrative regions.
Based on product, the immunosuppressants segment is poised to grow at 7.0% CAGR through 2034. By application, the HIV category will record a CAGR of 6.9% from 2024 to 2034.
| Top Segment | Immunosuppressants (Product) |
|---|---|
| CAGR (2024 to 2034) | 7.0% |
Despite a close contest, immunosuppressants remain the highly sought-after products, and the trend will probably persist through 2034. This can be attributed to rising adoption of these drugs for treating different autoimmune disorders.
As per the latest analysis, the target segment accounted for a prominent revenue share of 51% in 2023. Over the next decade, demand for immunosuppressants like corticosteroids (prednisone) sirolimus, azathioprine, and corticosteroids is forecast to surge at 7.0% CAGR.
Immunosuppressants are increasingly used to manage autoimmune diseases like psoriasis and rheumatoid arthritis. This is due to their tendency to control the overactive immune response and alleviate symptoms. Thus, growing prevalence of autoimmune disorders will directly influence immunosuppressant sales through 2034.
Increasing application of immunosuppressants in transplant medicine is another factor behind their rising fame. These drugs play a key role in preventing transplant rejection by dampening the immune response after organ transplant.
| Top Segment | HIV (Application) |
|---|---|
| CAGR (2024 to 2034) | 6.9% |
Based on application, HIV segment held 32% of the global immunomodulator market share in 2023. For the next ten years, a CAGR of 6.9% has been predicted for the target segment as cases of human immunodeficiency virus (HIV) continue to upsurge.
In recent years, there has been a spike in HIV cases globally, and new infections have not declined as much as hoped. This is creating a higher demand for HIV treatments like antiretroviral therapy (ART) and immunotherapies.
According to the United Nations International Children’s Emergency Fund (UNICEF), around 1.9 million children and adolescents are estimated to be living with HIV in 2030. This high HIV burden will ensure that there will be a constant demand for drugs.
Limited treatment options for HIV are also enhancing the popularity of immunotherapies. These medications help strengthen the immune systems to better fight HIV as well as slow disease progression.
With immunotherapy becoming a highly evolving field, several opportunities exist for manufacturers of immune system modulators. To capitalize on emerging opportunities, players are rigorously investing in research and development to produce new immunotherapies. For instance, they are looking to develop novel drugs that target specific diseases like autoimmune disorders and cancer.
Several companies are collaborating and partnering with other companies and research institutions to facilitate drug development processes and reduce complexities and costs. Similarly, the market is witnessing strategies like collaborations, acquisitions, and mergers as players look to strengthen their presence globally and stay ahead of the curve.
Recent Developments
| Date and Approach | Description |
|---|---|
| February 2024, Clinical Trial | The United States-based Nuvig Therapeutics, Inc., which develops novel immune modulatory therapeutics for patients with inflammatory autoimmune diseases, started early-stage trials for an advanced NVG-2089 immuno-modulator. |
| August 2023, Drug Approval | The Janssen Pharmaceuticals Companies (headquartered in Belgium) of Johnson & Johnson received FDA approval for TALVEY, a first-in-class bispecific therapy to treat adult patients with heavily pretreated multiple myeloma. |
| December 2022, Collaboration | The American multinational pharmaceutical company Merck collaborated with Mersana Therapeutics to discover and develop new immunostimulatory antibody conjugates (ADCs). |
| February 2023, Drug Approval Request | The United States-based Sage Therapeutics and Biogen, a leading American multinational biotechnology company, stated that the United States Food and Drug Administration (FDA) has accepted the filling of a new drug application for zuranolone in the treatment of postpartum depression and depressive disorder (MDD). |
| April 2019, Acquisition | The Swiss multinational pharmaceutical company Novartis acquired IFM Tre to strengthen its portfolio of immune-modulatory medicines. |
The global market is forecast to total USD 88.6 billion in 2024.
Global demand is set to grow at a CAGR of 7.2% through 2034.
By 2034, the global market size is predicted to reach USD 178.0 billion.
The target industry registered a CAGR of 9.4% from 2019 to 2023.
Sales in the United States are anticipated to soar at 7.5% CAGR through 2034.
Cytokines, checkpoint inhibitors, agonists, and adjuvants.
Rituximab (Rituxan), infliximab (Remicade), and abatacept (Orencia) are few popular brands.
Immunomodulatory drugs are used to manage cancer, infection, allergy, and other diseases.
Immunomodulators are substances that stimulate or suppress the immune system.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 5.1. Immunosuppressants 5.2. Immunostimulants 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 6.1. Oncology 6.2. Respiratory 6.3. HIV 6.4. Others 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. F. Hoffmann-La Roche Ltd. 17.2. Biogen Inc. 17.3. Teva Pharmaceutical Industries Ltd. 17.4. Novartis AG 17.5. Amgen, Inc. 17.6. Bristol-Myers Squibb Company 17.7. Merck Sharp & Dohme Corp. 17.8. Eli Lilly and Company 17.9. Abbott Laboratories 17.10. Johnson & Johnson 17.11. Pfizer Inc. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Immunomodulator Market
